HC Wainwright Has Lowered Expectations for EyePoint Pharmaceuticals (NASDAQ:EYPT) Stock Price

EyePoint Pharmaceuticals (NASDAQ:EYPT) had its price target cut by HC Wainwright from $30.00 to $22.00 in a research report report published on Monday,Benzinga reports. They currently have a buy rating on the stock. HC Wainwright also issued estimates for EyePoint Pharmaceuticals’ FY2024 earnings at ($2.15) EPS, Q1 2025 earnings at ($0.44) EPS, Q2 2025 earnings at ($0.45) EPS, Q3 2025 earnings at ($0.59) EPS, Q4 2025 earnings at ($0.59) EPS and FY2025 earnings at ($2.06) EPS.

Several other equities research analysts have also commented on EYPT. StockNews.com upgraded EyePoint Pharmaceuticals to a “sell” rating in a research report on Saturday, September 21st. Jefferies Financial Group assumed coverage on shares of EyePoint Pharmaceuticals in a report on Wednesday, August 28th. They issued a “buy” rating and a $15.00 price objective for the company. Chardan Capital increased their target price on shares of EyePoint Pharmaceuticals from $28.00 to $33.00 and gave the stock a “buy” rating in a research note on Friday, November 8th. Robert W. Baird cut their price target on EyePoint Pharmaceuticals from $38.00 to $33.00 and set an “outperform” rating for the company in a research note on Monday. Finally, Scotiabank assumed coverage on EyePoint Pharmaceuticals in a report on Wednesday, October 16th. They issued a “sector outperform” rating and a $18.00 price target for the company. One investment analyst has rated the stock with a sell rating and nine have issued a buy rating to the stock. According to data from MarketBeat, EyePoint Pharmaceuticals currently has a consensus rating of “Moderate Buy” and a consensus target price of $28.00.

EyePoint Pharmaceuticals Stock Performance

NASDAQ EYPT opened at $10.49 on Monday. The firm has a market capitalization of $561.42 million, a P/E ratio of -5.25 and a beta of 1.50. The stock has a 50-day simple moving average of $9.71 and a two-hundred day simple moving average of $9.91. EyePoint Pharmaceuticals has a fifty-two week low of $5.86 and a fifty-two week high of $30.99.

Institutional Trading of EyePoint Pharmaceuticals

Large investors have recently bought and sold shares of the business. Vanguard Group Inc. grew its stake in shares of EyePoint Pharmaceuticals by 17.8% in the 1st quarter. Vanguard Group Inc. now owns 2,396,228 shares of the company’s stock valued at $49,530,000 after buying an additional 362,168 shares during the period. RA Capital Management L.P. acquired a new stake in shares of EyePoint Pharmaceuticals during the 1st quarter worth about $19,401,000. Deerfield Management Company L.P. Series C lifted its position in shares of EyePoint Pharmaceuticals by 51.4% during the 2nd quarter. Deerfield Management Company L.P. Series C now owns 877,790 shares of the company’s stock worth $7,637,000 after buying an additional 298,196 shares during the last quarter. Fiera Capital Corp lifted its holdings in shares of EyePoint Pharmaceuticals by 0.9% in the 2nd quarter. Fiera Capital Corp now owns 677,038 shares of the company’s stock valued at $5,890,000 after purchasing an additional 5,920 shares during the last quarter. Finally, Perceptive Advisors LLC boosted its holdings in shares of EyePoint Pharmaceuticals by 8.6% in the second quarter. Perceptive Advisors LLC now owns 640,274 shares of the company’s stock valued at $5,570,000 after acquiring an additional 50,628 shares during the period. Hedge funds and other institutional investors own 99.41% of the company’s stock.

EyePoint Pharmaceuticals Company Profile

EyePoint Pharmaceuticals, Inc, a clinical-stage biopharmaceutical company, engages in developing and commercializing therapeutics to improve the lives of patients with serious retinal diseases. The company's pipeline leverages its proprietary bioerodible Durasert E technology for sustained intraocular drug delivery.